Skip to main content
PolyPeptide Group AG logo

PolyPeptide Group AG — Investor Relations & Filings

Ticker · PPGN ISIN · CH1110760852 LEI · 5067007JCKTPOX4G9758 SW Manufacturing
Open in API
Filings indexed 111 across all filing types
Latest filing 2023-10-31 Environmental & Social …
Country CH Switzerland
Listing SW PPGN

About PolyPeptide Group AG

https://www.polypeptide.com/

PolyPeptide Group AG is a Contract Development & Manufacturing Organization (CDMO) specializing in peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). The company serves the pharmaceutical and biotech sectors by providing a comprehensive range of services that cover all stages of product development, from pre-clinical to commercial manufacturing. Its offerings include both proprietary (custom) and generic GMP-grade peptides. PolyPeptide focuses on innovation in peptide synthesis and manufacturing processes to support the development of therapies for patients.

Recent filings

Filing Released Lang Actions
PolyPeptide unterzeichnet wissenschaftliche Kollaborationsvereinbarung
Environmental & Social Information Classification · 99% confidence The document is explicitly labeled as a "Medienmitteilung" (Media Release) dated 31.10.2023. It announces a specific corporate event: signing a scientific collaboration agreement focused on improving sustainability in peptide manufacturing. This type of announcement, which is a general corporate update that doesn't fit neatly into specific financial reporting categories (like 10-K, ER, or DIV), is best classified as a general regulatory announcement or news release. Since it is not a formal financial report, a proxy statement, or an earnings release, and it is a specific, non-standard announcement, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate news releases not covered by other specific codes. The document length is moderate (5207 chars), but its content is purely informational news, not a detailed report itself.
2023-10-31 German
PolyPeptide secures revolving credit facility
Capital/Financing Update Classification · 98% confidence The document is a 'Media Release' dated October 2, 2023, announcing that 'PolyPeptide secures revolving credit facility'. The content details the signing of a new EUR 111 million revolving credit facility (RCF) and the extension of an existing facility with its shareholder. This clearly relates to the company's fundraising and capital structure activities. Based on the provided definitions, this aligns best with the 'Capital/Financing Update' category (Code: CAP). The document is short and is an announcement, but the core subject matter is the financing event itself, not just the announcement of a report, making CAP more specific than RPA or RNS.
2023-10-02 English
PolyPeptide secures revolving credit facility
Capital/Financing Update Classification · 99% confidence The document is a 'Media Release' dated 02.10.2023 announcing that 'PolyPeptide secures revolving credit facility'. It details the signing of a new EUR 111 million revolving credit facility (RCF) and the extension of a facility with its majority shareholder. This content directly relates to the company's fundraising, financing activities, and capital structure adjustments. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2023-10-02 English
PolyPeptide sichert revolvierende Kreditfazilität
Capital/Financing Update Classification · 98% confidence The document is a 'Medienmitteilung' (Media Release) dated 02.10.2023, announcing that PolyPeptide Group has secured a revolving credit facility ('revolvierende Kreditfazilität') and extended a facility with its majority shareholder. This action directly relates to the company's financing activities and capital structure management. Based on the definitions, this clearly falls under 'Capital/Financing Update' (CAP). Although it is a press release, the core content is the financing event itself, not just an announcement that a report is attached (which would suggest RPA or RNS). The document details the terms of the new EUR 111 million RCF and the EUR 40 million extension.
2023-10-02 German
Transformational progress taking shape, profitability impacted by rapid expansion appointment of Marc Augustin as new CFO
Earnings Release Classification · 100% confidence The document explicitly states it is announcing 'results for H1 2023' and provides detailed, unaudited financial tables (Revenue, EBITDA, Net result) for the first half of the year. This content structure is characteristic of a comprehensive interim financial report. The document also mentions an 'Audio webcast and conference call' and links to the 'Half-year Report 2023'. Since this document contains the detailed results and analysis, it is classified as an Interim/Quarterly Report (IR), not just a publication announcement (RPA). The mention of 'H1 2023' confirms the interim nature. H1 2023
2023-08-15 English
Transformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO
Interim / Quarterly Report Classification · 95% confidence The document is a detailed 'ad hoc announcement' regarding PolyPeptide Group's H1 2023 financial results. It contains comprehensive financial tables (Revenue, EBITDA, EBIT, EPS, etc.), management commentary on business performance, strategic updates, and guidance. While it mentions that a full 'Half-year Report 2023' is available via a link, the document itself provides substantial financial data and analysis, qualifying it as an Interim/Quarterly Report (IR) rather than a mere publication announcement (RPA). H1 2023
2023-08-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.